Gene edit in small human trial sharply cuts LDL cholesterol, raising hopes for one-time treatment
Scientists report a first-in-human base-editing trial that disrupted PCSK9 in liver cells, producing up to a 55% LDL cholesterol reduction after one infusion, offering potential for a one-time therapy but raising safety, ethical and access questions.
- First-in-human base editing: A single-dose, liver-targeted base editor (VERVE-101) reduced LDL cholesterol up to ~55% in a small pilot study.
- Gene-level proof: Liver biopsies confirmed the intended PCSK9 DNA change in targeted cells, demonstrating editing in humans.
- Safety caveats: Most side effects were mild, but two participants had serious cardiac events during follow-up; causality remains unclear.
- Broader stakes: The approach could offer a one-time alternative to lifelong cholesterol drugs, but raises safety, ethical and access questions for patients and systems.
What happened
In the VERVE-101 pilot study, researchers used base editing — a refined form of CRISPR that swaps single DNA letters without cutting both DNA strands — to disable the PCSK9 gene in liver cells. Participants received a single infusion of lipid nanoparticles carrying the base editor instructions. The treatment produced LDL cholesterol reductions as large as about 55% from baseline in some patients, according to the published report.
Who ran the trial
The VERVE-101 early Phase 1 pilot study was conducted by Verve Therapeutics in collaboration with clinicians at Royal Perth Hospital in Australia. Findings and context were reported in the New England Journal of Medicine (original study), Nov. 4, 2023 and in company materials released by Verve Therapeutics press materials.
How the treatment works
VERVE-101 uses lipid nanoparticles to deliver a base editor to liver cells. The editor makes a precise, single-letter change in the PCSK9 gene, reducing PCSK9 protein production. With lower PCSK9, the liver retains more LDL receptors and clears more LDL cholesterol from the blood.
Why base editing? Unlike older CRISPR approaches that cut both DNA strands, base editing edits single DNA bases without double-strand breaks, aiming to lower the risk of unintended genomic changes.
Trial design and results
VERVE-101 is an early Phase 1 effort enrolling a small number of adults with very high LDL and existing heart disease who could not tolerate standard cholesterol drugs. Participants received a one-time infusion and were followed closely for biochemical, histologic and clinical outcomes.
- Gene editing evidence: Liver biopsies showed the intended PCSK9 edit in targeted cells, verifying human DNA editing.
- Cholesterol reductions: The largest LDL drop observed was about 55% from baseline; several participants had meaningful, lasting LDL declines after a single dose.
- Safety signals: Most adverse events were mild and short-lived; however, two participants experienced serious cardiac events during follow-up. Investigators noted these occurred in people with advanced heart disease and were not clearly attributed to the therapy.
Expert views: promise and caution
“Our dream really is to offer a one-time treatment that could replace lifelong medicines,” said Dr. Sekar Kathiresan, CEO of Verve Therapeutics.
Independent experts described the results as a major step forward but urged caution. Early trials can overstate benefits and understate rare harms, and any permanent edit requires long-term surveillance for delayed effects and potential off-target changes. Base editing reduces but does not eliminate the need to monitor for unintended edits to other genes.
Safety, ethics and access questions
Safety: Long-term safety and rare adverse events remain unknown; regulators will expect larger, diverse trials with long follow-up.
Ethics and policy: A permanent, potentially expensive one-time therapy raises questions about who should be offered treatment, how to price and reimburse it, and how regulators balance irreversible benefit versus risk.
Access: Insurance coverage, equitable distribution and long-term registries to track outcomes will be crucial if the therapy progresses.
Implications for Las Vegas, Nevada
Economic impact: Local cardiology services and hospitals could need new training and infusion infrastructure if one-time gene-editing treatments become available, potentially prompting investments in specialty clinics.
Cost and equity: Las Vegas serves many uninsured and Medicaid patients; an expensive therapy could widen disparities unless policymakers and systems negotiate coverage or safety-net access.
Policy and public health: Nevada regulators and lawmakers may weigh reimbursement policies, surveillance programs and public messaging to balance innovation with prevention and affordable care.
Practical guidance for residents: At present, only patients with severe cholesterol problems not helped by standard drugs were eligible for the trial. Most people should continue evidence-based treatments like statins and lifestyle measures until more data are available.
Next steps in research and regulation
Researchers plan to expand trials, enroll more participants, and lengthen follow-up to monitor durability and rare adverse events. Regulators will review accumulating data as Verve and independent investigators assess off-target effects, long-term durability and clinical outcomes.
Reporting and sources
- New England Journal of Medicine (original study), Nov. 4, 2023
- Verve Therapeutics press materials
- Reuters coverage
- New York Times coverage
This article summarizes the published pilot study and reporting from major outlets. Local readers with questions about cholesterol management should consult their physicians.
